Regulatory News : BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative company dedicated to the development of...
Obtention de l’autorisation de mise sur le marché aux Etats-Unis pour Sitavig® Ouverture des études cliniques Livatag® (phase III...
Regulatory News : BioAlliance Pharma (Paris:BIO) : Pursuant to article L.233-8 II of the Code de commerce (the French Commercial...
Regulatory News : BioAlliance Pharma (Paris:BIO) : Conformément à l’article L. 233-8 II du Code de commerce et à l’article 223-16...
Montant brut levé : 8,7 millions d’euros ; Opération sursouscrite à hauteur de 155 % ; Exercice de la clause d’extension.
Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company dedicated to the development of orphan oncology products and...
Regulatory News: BioAlliance Pharma (Paris:BIO): Pursuant to article L.233-8 II of the Code de commerce (the French Commercial...
Grant to support NICE: France’s first nanomedicine consortium led by BioAlliance Pharma
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.